Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and Cyramza in metastatic gastroesophageal cancer
NCT02317991Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2015
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel in gastroesophageal adenocarcinoma, sponsored by SCRI Development Innovations. Primary endpoint: Progression-Free Survival at 1 year. Started May 2015; status: completed.
02
Drugs
paclitaxel
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT02317991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317991.